Diamyd Medical Advances Type 1 Diabetes Therapy: FDA Green-Lights Faster Phase 3 Results Timeline

Waiting matters in clinical trials. Diamyd Medical just made type 1 diabetes treatment development significantly faster. The biotech company received FDA approval to shift its primary efficacy readout in the Phase 3 DIAGNODE-3 trial from 24 months to 15 months—cutting the wait time by nine months.

The Trial Acceleration: What Changed

The DIAGNODE-3 trial tests Diamyd, a precision-medicine approach designed to preserve endogenous insulin production in patients with Stage 3 type 1 diabetes. The study involves approximately 300 genetically defined participants. Originally, results would come at the two-year mark, but following a Type C meeting with regulators, the FDA agreed to accept 15-month data as the primary efficacy endpoint.

This acceleration doesn’t mean abandoning the original timeline entirely. The previously announced interim efficacy readout at 15 months—gathering data from roughly 170 participants—remains scheduled for the end of March 2026. The 24-month assessment will now function as a secondary endpoint, measuring the durability of the treatment effect over time.

Why This Matters for Type 1 Diabetes Treatment

The two co-primary efficacy endpoints being evaluated are C-peptide area under the curve (AUC), a marker of how well the body maintains endogenous insulin production, and HbA1c, which measures long-term blood sugar control. By hitting these targets at 15 months instead of 24, Diamyd may qualify for an accelerated Biologics License Application (BLA) pathway.

The FDA has already granted Diamyd three significant designations: Fast Track Designation for Stages 1-3 of type 1 diabetes, Orphan Drug Designation for Stage 3, and formal confirmation that C-peptide serves as an acceptable surrogate endpoint supporting accelerated approval. These regulatory benefits compress the typical approval timeline substantially.

The Broader Implications

For type 1 diabetes patients awaiting new therapeutic options, this acceleration represents real momentum. Precision-medicine immunotherapies targeting specific disease stages require rigorous validation, but moving the primary readout nine months earlier means evidence for efficacy could reach regulators and clinicians sooner. The shift also signals FDA confidence in both the trial design and Diamyd’s therapeutic approach—a positive signal for the broader field of antigen-specific immunotherapy in autoimmune conditions.